High Estrogen Receptor β Expression Is Prognostic among Adjuvant Chemotherapy–Treated Patients—Results from a Population-Based Breast Cancer Cohort

Elebro, Karin; Borgquist, Signe; Rosendahl, Ann H.; Markkula, Andrea; Simonsson, Maria; Jirström, Karin; Rose, Carsten; Ingvar, Christian; Jernström, Helena

doi:10.1158/1078-0432.ccr-16-1095

Cited by 27 publications

(26 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CTCs highly expressed HAND2, which is reported to decrease ESR1 transcriptional activity. 33 CTCs also strongly expressed WNT8A, 34 PIK3CB, 35 and ESR2, 36 in addition to the OR52H1, CATSPER4, and CLRN1 genes, which were not previously associated with breast cancer. EGFR was expressed in half of the CTCs (Fig.…”

Section: Discussionmentioning

confidence: 81%

RNA-Seq of Circulating Tumor Cells in Stage II–III Breast Cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 81%

RNA-Seq of Circulating Tumor Cells in Stage II–III Breast Cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Previous studies suggested that the high expression of an alternative ER isoform, ESR2 (encoding ERβ), was associated with favorable BC prognosis and that the association might depend on the ratio of ESR1 and ESR2 (ERα and ERβ) 24,25 . Consistently, we observed that patients with increasing ESR1/ESR2 ratio tended to have poorer survival (HR=1.5, 95% CI=0.7-3.3, P=0.27, adjusting for age and stage) in TCGA luminal patients.…”

Section: Discussionmentioning

confidence: 99%

Immune gene expression profiling reveals heterogeneity in luminal breast tumors

Zhu

Tse

Wang

et al. 2019

Preprint

View full text Add to dashboard Cite

Disease heterogeneity of immune gene expression patterns of luminal breast cancer (BC) has not been well studied. We performed immune gene expression profiling of tumor and adjacent normal tissue in 92 Asian luminal BC patients and identified three distinct immune subtypes. Tumors in one subtype exhibited signs of T-cell activation, lower ESR1/ESR2 expression ratio and higher expression of immune checkpoint genes, nonsynonymous mutation burden, APOBEC-signature mutations, and increasing body mass index compared to other luminal tumors. Tumors in a second subtype were characterized by increased expression of interferonstimulated genes and enrichment for TP53 somatic mutations. The presence of three immune subtypes within luminal BC was replicated in cases drawn from The Cancer Genome Atlas and a Korean breast cancer study. Our findings suggest that immune gene expression and associated genomic features could be useful to further stratify luminal BC beyond the current luminal A/B classification.Introduction:

show abstract

“…Upregulation of ERb1 or its splice variant ERb5 enhanced the efficacy of doxorubicin and cisplatin in breast cancer cells (31,32). Consistently, high expression of ERb1 has recently been associated with better prognosis in chemotherapy-treated ERa-negative breast cancer (33,34). In addition, ligand-mediated activation of ERb has been shown to sensitize malignant pleural mesothelioma cells to cisplatin and pemetrexed therapy by suppressing AKT signaling that leads to PARP-dependent proapoptotic cell death (35).…”

Section: Introductionmentioning

confidence: 88%

“…High expression of ERb1 has been associated with better prognosis in chemotherapy-treated breast cancer patients (33). To investigate whether a similar association occurs in lung cancer, we tested the correlation between ERb1 and survival in published Kaplan-Meier plotter datasets (38) and found that chemotherapy-treated ESR2 high NSCLC patients have better clinical outcome compared with ESR2 low patients (Supplementary Fig.…”

Section: Erb1 Sensitizes P53-defective Nsclc Cells To Chemotherapeutimentioning

confidence: 96%

ERβ Sensitizes NSCLC to Chemotherapy by Regulating DNA Damage Response

Nikolos

Thomas

Bado

et al. 2018

Molecular Cancer Research

View full text Add to dashboard Cite

The expression of wild-type estrogen receptor β (ESR2/ERβ1) correlates with clinical outcome in patients with non-small cell lung cancer (NSCLC). However, the molecular mechanism that accounts for this association is currently poorly understood. ERβ1 was previously linked to chemotherapy response in patients with breast cancer and in breast cancer cells. The effect of the receptor in NSCLC cells after chemotherapy treatment, a common remedy for advanced NSCLC, has not been studied. Here, upregulation of ERβ1 increases the sensitivity of NSCLC cells to treatment with doxorubicin and etoposide. This effect was primarily observed in p53-defecient NSCLC cells. In these cells, ERβ1 either enhanced G-M cell-cycle arrest by activating the checkpoint kinase 1 (Chk1) and altering downstream signaling or induced apoptosis. The expression of p63 target genes that control G-M checkpoint activation was altered by ERβ1 suggesting an ERβ1-p63 transcriptional cooperation in lung cancer cells that affects DNA damage response (DDR). These results suggest involvement of ERβ1 in the mechanism that regulates DNA damage response in NSCLC cells and support the potential predictive and therapeutic value of the receptor in clinical management of the disease. This study demonstrating the impact of ERβ1 on chemosensitivity of NSCLC cells suggests the predictive value of the receptor for successful response of tumors to chemotherapy and the potential benefit of chemotherapy-treated patients from the use of ER ligands. .

show abstract

High Estrogen Receptor β Expression Is Prognostic among Adjuvant Chemotherapy–Treated Patients—Results from a Population-Based Breast Cancer Cohort

Cited by 27 publications

References 52 publications

RNA-Seq of Circulating Tumor Cells in Stage II–III Breast Cancer

RNA-Seq of Circulating Tumor Cells in Stage II–III Breast Cancer

Immune gene expression profiling reveals heterogeneity in luminal breast tumors

ERβ Sensitizes NSCLC to Chemotherapy by Regulating DNA Damage Response

Contact Info

Product

Resources

About